专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070105165A1 Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers 审中-公开
标题翻译：细胞抗原和靶信号转导蛋白的复合谱，用于分析和临床管理血液癌
公开(公告)号：US20070105165A1
公开(公告)日：2007-05-10
申请号：US11267948
申请日：2005-11-04
申请人： Charles Goolsby , T. Shankey , David Hedley , James Jacobberger , Stanley Shackney
发明人： Charles Goolsby , T. Shankey , David Hedley , James Jacobberger , Stanley Shackney
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , G01N33/5052 , G01N2800/52
摘要： The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
摘要翻译：本发明涉及用于建立来自疑似具有肿瘤状况的个体的样品的复合标记物谱的方法。本发明的复合标记物分布允许鉴定预后和治疗相关的肿瘤病症亚组和个体临床病程的预测。本发明的方法提供了用于选择患有肿瘤病症的个体的治疗的工具，包括分配风险组的方法，预测复发风险增加的方法，预测发生继发性并发症的风险增加的方法，方法选择个体治疗的方法，确定个体治疗功效的方法以及确定个体预后的方法。特别地，本发明的方法公开了一种建立复合标记物谱的方法，该方法可用作预后指标以预测个体肿瘤状况的进程是否是侵略性或惰性的，由此帮助临床医师管理患者和评估使用的治疗方式。在本文公开的特定实施方案中，本发明的方法涉及建立选自慢性淋巴细胞性白血病（CLL），急性骨髓性白血病（AML），慢性骨髓性白血病（CML）和急性淋巴细胞性白血病（ALL）。

2. 发明申请

US20100261204A1 Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers 审中-公开
标题翻译：复合型细胞抗原和目标信号转导蛋白用于分析和临床管理的血液癌
公开(公告)号：US20100261204A1
公开(公告)日：2010-10-14
申请号：US12696702
申请日：2010-01-29
申请人： Charles GOOLSBY , T. Vincent Shankey , David Hedley , James Jacobberger , Stanley Shackney
发明人： Charles GOOLSBY , T. Vincent Shankey , David Hedley , James Jacobberger , Stanley Shackney
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , G01N33/5052 , G01N2800/52
摘要： The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
摘要翻译：本发明涉及用于建立来自疑似具有肿瘤状况的个体的样品的复合标记物谱的方法。本发明的复合标记物分布允许鉴定预后和治疗相关的肿瘤病症亚组和个体临床病程的预测。本发明的方法提供了用于选择患有肿瘤病症的个体的治疗的工具，包括分配风险组的方法，预测复发风险增加的方法，预测发生继发性并发症的风险增加的方法，方法选择个体治疗的方法，确定个体治疗功效的方法以及确定个体预后的方法。特别地，本发明的方法公开了一种建立复合标记物谱的方法，该方法可用作预后指标以预测个体肿瘤状况的进程是否是侵略性或惰性的，由此帮助临床医师管理患者和评估使用的治疗方式。在本文公开的特定实施方案中，本发明的方法涉及建立选自慢性淋巴细胞性白血病（CLL），急性骨髓性白血病（AML），慢性骨髓性白血病（CML）和急性淋巴细胞性白血病（ALL）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式